Menu
Back to Journals » Cancer Management and Research » Volume 7
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Authors Greasley R, Khabazhaitajer M, Rosario D
Received 9 June 2014
Accepted for publication 7 September 2014
Published 12 June 2015 Volume 2015:7 Pages 153—164
DOI https://doi.org/10.2147/CMAR.S50585
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Professor Kenan Onel
Rosa Greasley,1 Mohammad Khabazhaitajer,1 Derek J Rosario2
1The Department of Oncology, The University of Sheffield, Sheffield, UK; 2The Department of Urology, Sheffield Teaching Hospitals, The Royal Hallamshire Hospital, Sheffield, UK
Abstract: Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a novel androgen-receptor signaling inhibitor, has emerged targeting multiple steps within the androgenic stimulation pathway. This review discusses what is currently known of the mechanisms surrounding castration resistant prostate cancer development and the current human clinical trials to determine whether enzalutamide presents a new hope for men with advanced prostate cancer. The issues of therapy resistance, withdrawal effects and cross-resistance are briefly touched upon.
Keywords: enzalutamide, androgen receptor, metastatic castrate resistant prostate cancer, MDV3100, anti-androgen
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.